Charles Schwab Investment Management Inc Lyell Immunopharma, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 1,147,370 shares of LYEL stock, worth $711,369. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,147,370
Previous 1,297,642
11.58%
Holding current value
$711,369
Previous $1.88 Million
15.84%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding LYEL
# of Institutions
121Shares Held
142MCall Options Held
18.1KPut Options Held
200-
Mwg Management Ltd. Washington, DC20.2MShares$12.5 Million30.81% of portfolio
-
Apoletto LTD Washington, DC15.1MShares$9.36 Million42.56% of portfolio
-
Orland Properties LTD Washington, DC15.1MShares$9.36 Million13.96% of portfolio
-
Black Rock Inc. New York, NY13.5MShares$8.37 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$6.24 Million0.0% of portfolio
About Lyell Immunopharma, Inc.
- Ticker LYEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 247,824,992
- Market Cap $154M
- Description
- Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...